Reid Huber
About Reid Huber
Reid Huber, Ph.D. (age 53) is a Class I director at Rapport Therapeutics, serving on the board since February 2022; he previously served as Rapport’s President and Chief Executive Officer from February 2022 to February 2023. He is a Partner at Third Rock Ventures (since December 2018) and CEO of Merida Biosciences (since July 2022); prior roles include CEO of MOMA Therapeutics (April 2021–April 2022). Dr. Huber holds a B.S. in molecular genetics/biochemistry (Murray State University) and a Ph.D. in molecular genetics (Washington University School of Medicine), with pre/post-doctoral fellowships at the National Institutes of Health .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Rapport Therapeutics, Inc. | President & Chief Executive Officer | Feb 2022 – Feb 2023 | Oversaw transition to current CEO; board considered his senior management experience valuable |
| MOMA Therapeutics, Inc. | Chief Executive Officer | Apr 2021 – Apr 2022 | Not disclosed |
| National Institutes of Health | Pre- and Post-doctoral Fellow | Not disclosed (pre/post PhD) | Not disclosed |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Third Rock Ventures LLC | Partner | Dec 2018 – Present | Affiliation with major shareholder (entities affiliated with Third Rock beneficially own 22.21%) |
| Merida Biosciences | Chief Executive Officer | Jul 2022 – Present | Not disclosed |
| Bellicum Pharmaceuticals, Inc. (prev. Nasdaq: BLCM) | Director | Oct 2014 – Present | Not disclosed |
| CARGO Therapeutics, Inc. (Nasdaq: CRGX) | Director | Mar 2023 – Present | Not disclosed |
| Tango Therapeutics, Inc. (Nasdaq: TNGX) | Director | Jul 2019 – Nov 2023 | Not disclosed |
| American Cancer Society | Director | Not disclosed | Not disclosed |
Board Governance
| Item | Details |
|---|---|
| Board classification | Class I director; nominee for re-election at 2025 annual meeting to serve until 2028 |
| Committee assignments | Science & Technology Committee member; not on Audit, Compensation, or Nominating & Corporate Governance |
| Committee chairs | Science & Technology chaired by Wendy B. Young, Ph.D. |
| Board attendance | Full Board met 5 times in FY2024; each incumbent director attended ≥75% of aggregate Board and applicable committee meetings in FY2024 |
| S&T Committee activity | Committee met 5 times in FY2024 |
| Executive sessions | Non-employee directors met in executive session during each regularly scheduled Board meeting in FY2024 |
| Independence determination | As of March 2025, Board determined all directors except CEO Abraham Ceesay and Dr. Huber are independent under Nasdaq/SEC rules (i.e., Huber is not independent) |
| Board leadership | Chair and CEO roles separated; chair is Steven M. Paul, M.D. |
Fixed Compensation
| Component | FY2024 Amount (USD) | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $26,699 | Director cash compensation for services in 2024 |
| Option Awards | $— | No director option award value recognized for Huber in 2024 |
| Total | $26,699 | Sum of cash and equity award compensation |
Director compensation policy (adopted June 2024):
| Role | Annual Cash Retainer (USD) |
|---|---|
| Board member | $40,000 |
| Audit Committee – Chair / Member | $15,000 / $7,500 |
| Compensation Committee – Chair / Member | $10,000 / $5,000 |
| Nominating & Corporate Governance – Chair / Member | $8,000 / $4,000 |
| Science & Technology – Chair / Member | $8,000 / $4,000 |
Performance Compensation
| Equity Award | Grant Size | Vesting | Special Terms |
|---|---|---|---|
| Initial Director Grant (stock option) | 29,756 shares | 1/3 at 1-year anniversary; remaining 2/3 monthly over 24 months | Full accelerated vesting upon sale of the company |
| Director Annual Grant (stock option) | 14,878 shares | Vests in full by earlier of 1 year or next annual meeting | Prorated if appointed between annual meetings; accelerated on sale |
| Huber’s outstanding director equity at 12/31/2024 | RS/RSU: —; Options: — | — | No outstanding director stock awards/options reported |
No performance-based metrics (e.g., TSR, EBITDA) are disclosed for director compensation; director equity awards are time-based options per policy .
Other Directorships & Interlocks
| Company | Ticker | Role | Interlock / Potential Conflict |
|---|---|---|---|
| CARGO Therapeutics | CRGX | Director | None disclosed |
| Tango Therapeutics | TNGX | Former Director (2019–2023) | None disclosed |
| Bellicum Pharmaceuticals | — | Director | None disclosed |
| Third Rock Ventures (major RAPP holder) | — | Partner | Entities affiliated with Third Rock beneficially own 22.21% of RAPP; Huber is a partner at TRV (not independent) |
Expertise & Qualifications
- Extensive pharmaceutical/biotech senior management experience; Rapport CEO (2022–2023), CEO at MOMA Therapeutics; Partner at TRV; multiple public company boards .
- Scientific credentials: Ph.D. in molecular genetics; NIH pre/post-doctoral fellow; deemed qualified by the Board for industry expertise and senior management background .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class |
|---|---|---|
| Reid Huber, Ph.D. | — | — (not listed as beneficial owner as of Apr 21, 2025) |
Policy constraints:
- Hedging and pledging of company stock are prohibited for directors; short sales and derivatives are disallowed .
- Rule 10b5-1 trading plans permitted subject to compliance and not while in possession of MNPI .
- Compensation recovery (clawback) policy adopted May 29, 2024 (effective June 6, 2024) for incentive-based compensation tied to financial reporting measures in the event of restatements (executive officers) .
Governance Assessment
- Independence and conflicts: RED FLAG – Board determined Huber is not independent (March 2025), and he is a Partner at Third Rock Ventures, which holds 22.21% of RAPP; historical related financing involved Third Rock (Series B, $499,999 purchase), elevating potential conflict and influence risks .
- Committee effectiveness: Huber serves on Science & Technology, which met 5 times in FY2024; Board-level risk oversight is distributed, with attendance ≥75% and regular executive sessions, supporting engagement .
- Alignment: RED FLAG – No reported beneficial ownership or outstanding director options as of 12/31/2024; FY2024 director compensation for Huber was cash-only ($26,699), which may limit equity alignment pending application of post-IPO director option policy .
- Director compensation structure: Standard retainer plus time-based option grants (initial and annual) with full acceleration upon sale of company; acceleration could incentivize sale outcomes—investors should assess board independence alongside potential sale incentives .
- Related-party governance: Company adopted a formal related party transaction approval policy at IPO (>$120k threshold), overseen by Board/audit committee—appropriate safeguard given major holder affiliations among directors .
- Compensation committee oversight: Uses independent consultant Aon; independence evaluated with no conflicts found, which supports pay governance quality (committee chaired by James Healy; members include Maraganore, Perez, Sanchez) .
Related Party Transactions (Context)
| Related Party | Transaction | Amount | Notes |
|---|---|---|---|
| Entities affiliated with Third Rock Ventures VI, L.P. | Series B Convertible Preferred Stock purchase | $499,999 | Part of Aug 2023/March 2024 Series B rounds; TRV-affiliated entities are >5% holders; Huber is a TRV Partner |
Director Compensation Policy Reference
- Cash retainers across board/committees; annual equity option grants with time-based vesting; annual total compensation caps $1,000,000 (first year as non-employee director) and $750,000 thereafter .
Additional Notes
- The Board currently consists of nine directors; Huber is a Class I nominee alongside John Maraganore and Wendy Young at the 2025 annual meeting .
- Audit committee is fully independent; Chair Paul M. Silva designated as financial expert; met 2 times in FY2024 .
Overall implication: Huber brings deep sector expertise and S&T committee engagement, but his non-independence coupled with Third Rock’s major ownership creates perceived conflict risks and weak equity alignment signals for this director. Investors should monitor application of the director option policy to Huber and any related-party transaction reviews to ensure robust safeguards remain effective .